• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form FWP filed by Merck & Company Inc.

    12/1/25 8:19:38 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRK alert in real time by email
    FWP 1 merck-fwp.htm FWP Document

    Issuer Free Writing Prospectus
    Filed under Rule 433
    Registration Statement No. 333-278066
    Pricing Term Sheet
    Merck & Co., Inc.
    December 1, 2025
    Floating Rate Notes due 2029
    3.850% Notes due 2029
    4.150% Notes due 2031
    4.450% Notes due 2032
    4.750% Notes due 2035
    5.500% Notes due 2046
    5.550% Notes due 2055
    5.700% Notes due 2065
    The 3.850% Notes due 2029, 4.150% Notes due 2031, 4.450% Notes due 2032, 4.750% Notes due 2035, 5.500% Notes due 2046, 5.550% Notes due 2055 and 5.700% Notes due 2065 are collectively referred to as the “Fixed Rate Notes.” The Fixed Rate Notes, together with the Floating Rate Notes due 2029, are collectively referred to as the “Notes.” Unless otherwise indicated, terms used but not defined herein have the meanings assigned to such terms in the preliminary prospectus supplement dated December 1, 2025 (the “Preliminary Prospectus Supplement”).
    Terms Applicable to the Notes
    Expected Ratings of the Notes:*
    Aa3 (stable) Moody’s / A+ (stable) S&P
    Trade Date:December 1, 2025
    Settlement Date:**
    December 4, 2025 (T+3)
    Joint Book-Running Managers:Citigroup Global Markets Inc., BNP Paribas Securities Corp., Deutsche Bank Securities Inc., HSBC Securities (USA) Inc.
    Co-Managers:Barclays Capital Inc., BofA Securities, Inc., Santander US Capital Markets LLC, DNB Carnegie, Inc., SG Americas Securities, LLC, Standard Chartered Bank, U.S. Bancorp Investments, Inc., Wells Fargo Securities, LLC, Academy Securities, Inc., Independence Point Securities LLC, MFR Securities, Inc., Penserra Securities LLC and Telsey Advisory Group LLC



    Terms Applicable to the Floating Rate Notes due 2029
    Size:$500,000,000
    Maturity Date:March 15, 2029
    Interest Payment Dates:March 15, June 15, September 15 and December 15, commencing March 15, 2026
    Interest Rate Basis:    Compounded SOFR
    Spread to Compounded SOFR:+57 bps
    Day Count:Actual/360
    Interest Reset Dates:    Each floating rate interest payment date
    Initial Interest Rate:The initial interest rate will be Compounded SOFR determined on March 12, 2026, plus 57 bps
    Interest Determination Date:The second U.S. Government Securities Business Day preceding each floating rate interest payment date.
    Interest Period:The period from and including a floating rate interest payment date (or, in the case of the initial interest period, from and including December 4, 2025) to, but excluding, the immediately succeeding floating rate interest payment date (such succeeding floating rate interest payment date, the “latter floating rate interest payment date”); provided that the final interest period for the Floating Rate Notes due 2029 will be the period from and including the floating rate interest payment date immediately preceding the maturity date of the Floating Rate Notes due 2029 to, but excluding, the maturity date.
    Observation Period:    The period from and including two U.S. Government Securities Business Days preceding the first date of such relevant interest period to but excluding two U.S. Government Securities Business Days preceding the latter floating rate interest payment date for such interest period; provided that the first Observation Period shall be the period from and including two U.S. Government Securities Business Days preceding the Settlement Date to, but excluding, the two U.S. Government Securities Business Days preceding the first floating rate interest payment date.
    Optional Redemption:The Floating Rate Notes due 2029 are not redeemable prior to their maturity.
    Calculation Agent:U.S. Bank Trust National Association
    Price to Public:100.000%
    Underwriting Discount:25 bps
    CUSIP:58933Y BV6
    ISIN:US58933YBV65



    Terms Applicable to the Fixed Rate Notes
    Title:3.850% Notes due 20294.150% Notes due 20314.450% Notes due 20324.750% Notes due 20355.500% Notes due 20465.550% Notes due 20555.700% Notes due 2065
    Size:$750,000,000$1,000,000,000$1,000,000,000$1,500,000,000$750,000,000$1,500,000,000$1,000,000,000
    Maturity Date:March 15, 2029March 15, 2031December 4, 2032December 4, 2035March 15, 2046December 4, 2055December 4, 2065
    Interest Payment Dates:March 15 and September 15, commencing March 15, 2026March 15 and September 15, commencing March 15, 2026June 4 and December 4, commencing June 4, 2026June 4 and December 4, commencing June 4, 2026March 15 and September 15, commencing March 15, 2026June 4 and December 4, commencing June 4, 2026June 4 and December 4, commencing June 4, 2026
    Coupon:3.850%4.150%4.450%4.750%5.500%5.550%5.700%
    Benchmark Treasury:UST 3.500% due November 15, 2028UST 3.500% due November 30, 2030UST 3.750% due November 30, 2032UST 4.000% due November 15, 2035UST 4.625% due November 15, 2045UST 4.750% due August 15, 2055UST 4.750% due August 15, 2055
    Benchmark Treasury Yield:3.550%3.671%3.864%4.090%4.714%4.747%4.747%
    Spread to Benchmark
    Treasury:
    T+35 bps
    T+50 bps
    T+60 bps
    T+70 bps
    T+80 bps
    T+85 bps
    T+100 bps
    Yield to Maturity:3.900%4.171%4.464%4.790%5.514%5.597%5.747%
    Day Count:30/36030/36030/36030/36030/36030/36030/360
    Price to Public:99.852%99.907%99.917%99.685%99.839%99.321%99.267%
    Underwriting Discount:25 bps35 bps37.5 bps45 bps72.5 bps75 bps80 bps

    Make-Whole Call:

    Prior to the applicable Par Call Date with respect to a series of Fixed Rate Notes, each such series of Fixed Rate Notes will be redeemable at our option, in whole or in part, at any time and from time to time, at a redemption price equal to the greater of:
    (i) (a) the sum of the present values of the remaining scheduled payments of principal and interest on the Fixed Rate Notes to be redeemed discounted to the redemption date (assuming the Fixed Rate Notes matured on the applicable Par Call Date) on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate plus 10 basis points with respect to the 2029 notes, the Treasury Rate plus 10 basis points with respect to the 2031 notes, the Treasury Rate plus 10 basis points with respect to the 2032 notes, the Treasury Rate plus 15 basis points with respect to the 2035 notes, the Treasury Rate plus 15 basis points with respect to the 2046 notes, the Treasury Rate plus 15 basis points with respect to the 2055 notes, and the Treasury Rate plus 15 basis points with respect to the 2065 notes less (b) interest accrued to, but excluding, the redemption date, and

    (ii) 100% of the principal amount of the Fixed Rate Notes to be redeemed,

    plus, in either case, accrued and unpaid interest thereon to, but excluding, the redemption date.



    Par Call:
    On or after the applicable Par Call Date, we may redeem the 2029 notes, the 2031 notes, the 2032 notes, the 2035 notes, the 2046 notes, the 2055 notes or the 2065 notes, in whole or in part, at any time and from time to time, at a redemption price equal to 100% of the principal amount of the 2029 notes, the 2031 notes, the 2032 notes, the 2035 notes, the 2046 notes, the 2055 notes or the 2065 notes being redeemed plus accrued and unpaid interest thereon to, but excluding, the redemption date.

    “Par Call Date” means February 15, 2029, the date that is one month prior to the maturity of the 2029 notes, February 15, 2031, the date that is one month prior to the maturity of the 2031 notes, October 4, 2032, the date that is two months prior to the maturity of the 2032 notes, September 4, 2035, the date that is three months prior to the maturity of the 2035 notes, September 15, 2045, the date that is six months prior to the maturity of the 2046 notes, June 4, 2055, the date that is six months prior to the maturity of the 2055 notes and June 4, 2065, the date that is six months prior to the maturity of the 2065 notes.
    Special Mandatory Redemption:If (i) the consummation of the Cidara Acquisition does not occur on or before the later of (x) May 13, 2026 or (y) such later date to which the termination date under the Merger Agreement as in effect on the closing date of this offering may be extended in accordance with the terms thereof (such later date, the “Special Mandatory Redemption End Date”), (ii) prior to the Special Mandatory Redemption End Date, the Merger Agreement is terminated or (iii) we otherwise notify the trustee that we will not pursue the consummation of the Cidara Acquisition, we will be required to redeem the Floating Rate Notes due 2029, the 2029 notes, 2031 notes, the 2032 notes, the 2046 notes and the 2065 notes (collectively with the Floating Rate Notes due 2029, the 2029 notes, the 2031 notes, the 2032 notes and the 2046 notes, the “SMR notes”) then outstanding at a special mandatory redemption price equal to 101% of the principal amount of the SMR notes to be redeemed plus accrued and unpaid interest thereon to, but excluding, the Special Mandatory Redemption Date.
    Use of Proceeds:
    We intend to use the net proceeds of this offering for general corporate purposes including, without limitation, to repay outstanding indebtedness, as well as potentially to fund a portion of the cash consideration and related fees and expenses payable in connection with the Cidara Acquisition.

    If (i) the Cidara Acquisition is not consummated on or prior to the Special Mandatory Redemption End Date, (ii) prior to the Special Mandatory Redemption End Date, the Merger Agreement is terminated or (iii) we otherwise notify the trustee that we will not pursue the consummation of the Cidara Acquisition, then we expect to use a portion of the net proceeds from this offering to redeem the SMR notes at the special mandatory redemption price, as described above under “Special Mandatory Redemption.” In that instance, the 2035 notes and the 2055 notes will remain outstanding, and we intend to use the remaining net proceeds of such notes for general corporate purposes as described above.
    CUSIP:58933Y BW458933Y BX258933Y BY058933Y BZ758933Y CA1 58933Y CB958933Y CC7
    ISIN:US58933YBW49US58933YBX22US58933YBY05US58933YBZ79US58933YCA10 US58933YCB92US58933YCC75

    *Note: A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time.
    **Note: We expect to deliver the Notes against payment therefor on the third business day following the Trade Date (such settlement being referred to as “T+3”). Under Rule 15c6-1 of the Exchange Act, trades in the secondary market generally are required to settle in one business day, unless the parties to a trade expressly agree otherwise. Accordingly, purchasers who wish to trade the Notes on any date prior to the business day before delivery will be required, by virtue of the fact that the Notes initially will settle in T+3, to specify alternative settlement arrangements to prevent a failed settlement and should consult their own advisors.
    The issuer has filed a preliminary prospectus supplement and registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the preliminary prospectus supplement, the prospectus in that registration statement, and other documents the issuer has filed with the SEC and that are incorporated by reference into the preliminary prospectus supplement for more complete information about the issuer and this offering. You may get these documents for free by visiting



    EDGAR on the SEC website at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling Citigroup Global Markets Inc. toll free at 1-800-831-9146, BNP Paribas Securities Corp. toll free at 1-800-854-5674, Deutsche Bank Securities Inc. collect at 1-800-503-4611 or HSBC Securities (USA) Inc. toll free at 1-866-811-8049. This pricing term sheet supplements the preliminary prospectus supplement issued by Merck & Co., Inc. on December 1, 2025 relating to its prospectus dated May 14, 2024.

    Get the next $MRK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MRK

    DatePrice TargetRatingAnalyst
    11/24/2025$125.00Equal Weight → Overweight
    Wells Fargo
    11/13/2025$105.00Sector Outperform
    Scotiabank
    10/13/2025$95.00Neutral
    Citigroup
    9/17/2025$90.00Buy → Hold
    Berenberg
    5/14/2025$84.00Buy → Neutral
    Citigroup
    4/22/2025$85.00Neutral
    Cantor Fitzgerald
    2/18/2025$128.00 → $105.00Buy → Hold
    Deutsche Bank
    2/10/2025$121.00 → $100.00Buy → Hold
    TD Cowen
    More analyst ratings

    $MRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Merck upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Merck from Equal Weight to Overweight and set a new price target of $125.00

    11/24/25 8:13:55 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scotiabank initiated coverage on Merck with a new price target

    Scotiabank initiated coverage of Merck with a rating of Sector Outperform and set a new price target of $105.00

    11/13/25 9:15:08 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup resumed coverage on Merck with a new price target

    Citigroup resumed coverage of Merck with a rating of Neutral and set a new price target of $95.00

    10/13/25 8:54:29 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRK
    SEC Filings

    View All

    SEC Form FWP filed by Merck & Company Inc.

    FWP - Merck & Co., Inc. (0000310158) (Subject)

    12/1/25 8:19:38 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Merck & Company Inc.

    424B5 - Merck & Co., Inc. (0000310158) (Filer)

    12/1/25 8:13:38 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 13F-HR filed by Merck & Company Inc.

    13F-HR - Merck & Co., Inc. (0000310158) (Filer)

    11/12/25 4:11:52 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thulin Inge G bought $250,000 worth of shares (2,833 units at $88.25), increasing direct ownership by 2,833% to 2,933 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    2/7/25 4:09:51 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Baker Douglas M Jr bought $1,327,500 worth of shares (15,000 units at $88.50), increasing direct ownership by 1,500% to 16,000 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    2/7/25 4:04:52 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now

    AUSTIN, Texas, Dec. 02, 2025 (GLOBE NEWSWIRE) -- BioMedWire: Chronic conditions and rare diseases in the aging population present an urgent and expanding challenge within the U.S. healthcare system, especially as more than 30 million Americans are affected by rare diseases, according to the National Institutes of Health. The vast majority of these conditions lack any FDA-approved treatment, leaving older adults especially vulnerable as age-related symptoms often obscure or delay diagnosis. This rising burden has increased demand for new therapies that can address real unmet need. Soligenix Inc. (NASDAQ:SNGX) (Profile), a late-stage biopharmaceutical company, is developing multiple treatmen

    12/2/25 8:30:00 AM ET
    $BMY
    $INSM
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025

    Merck granted Fast Track Designation by the U.S. FDA for MK-2214 for the treatment of Alzheimer's disease Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced plans to present first-in-human data for MK-2214 and MK-1167 at Clinical Trials on Alzheimer's Disease (CTAD) 2025 in San Diego, California from Dec. 1-4. In addition, the company announced that MK-2214, a novel candidate targeting the abnormal accumulation and aggregation of tau in the brain, has been granted Fast Track Designation by the U.S. Food and Drug Administration for the treatment of Alzheimer's disease. Fast Track is a process designed to facilitate the development and expedite the review

    12/1/25 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck to Participate in the Citi 2025 Global Healthcare Conference

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that Chirfi Guindo, chief marketing officer, Human Health, and Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories, are scheduled to participate in a fireside chat at the Citi 2025 Global Healthcare Conference on Wednesday, Dec. 3, 2025, at 1:00 p.m. ET. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at this weblink. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power

    11/26/25 7:15:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Comm. & Public Afrs Ofcr Downing Cristal N sold $616,395 worth of shares (7,085 units at $87.00), closing all direct ownership in the company (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    11/12/25 4:01:31 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP,Chief Info&Digital Officer Williams David Michael sold $720,040 worth of shares (8,614 units at $83.59), decreasing direct ownership by 26% to 24,578 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    11/4/25 4:02:03 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Seidman Christine E

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    10/2/25 9:31:14 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRK
    Financials

    Live finance-specific insights

    View All

    Merck Announces First-Quarter 2026 Dividend

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.85 per share of the company's common stock for the first quarter of 2026. Payment will be made on Jan. 8, 2026, to shareholders of record at the close of business on Dec. 15, 2025. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intens

    11/18/25 11:30:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results

    Total Worldwide Sales Were $17.3 Billion, an Increase of 4% From Third Quarter 2024; Excluding the Impact of Foreign Exchange, Sales Grew 3% KEYTRUDA Sales Grew 10% to $8.1 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 8% WINREVAIR Sales Were $360 Million; Growth of 141% Both Nominally and Excluding the Impact of Foreign Exchange CAPVAXIVE Sales Were $244 Million GARDASIL/GARDASIL 9 Sales Declined 24% to $1.7 Billion; Excluding the Impact of Foreign Exchange, Sales Declined 25% Animal Health Sales Grew 9% to $1.6 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 7% GAAP EPS Was $2.32; Non-GAAP EPS Was $2.58; GAAP and Non-GAAP EPS Include a Ch

    10/30/25 6:30:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck to Hold Third-Quarter 2025 Sales and Earnings Conference Call Oct. 30

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, will hold its third-quarter 2025 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, Oct. 30. During the call, company executives will provide an overview of Merck's performance for the quarter. Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available at www.merck.com. All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Fr

    10/1/25 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRK
    Leadership Updates

    Live Leadership Updates

    View All

    Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent

    CD388 is an investigational long-acting, strain-agnostic antiviral agent currently in Phase 3, designed to prevent influenza infection in individuals at higher risk of influenza complications Acquisition aligns with Merck's science-led business development strategy, diversifying and expanding the company's pipeline Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Cidara Therapeutics, Inc. (NASDAQ:CDTX) ("Cidara"), a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Cidara for $221.50 per share in cash, for a tot

    11/14/25 6:45:00 AM ET
    $CDTX
    $MRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    REPAY Appoints New Chief Financial Officer

    Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of integrated payment processing solutions, today announced the appointment of Robert Houser as Chief Financial Officer of the Company, effective September 8, 2025. "We are extremely excited to welcome Rob to REPAY. Rob brings over a decade of divisional CFO and operational experience within the payment industry to help him contribute immediately. Rob has held key strategic roles across his career and will be a great partner in running our company," said John Morris, Co-Founder and CEO. Most recently, Rob served as the Group CFO of the Public Sector and Advisor at Conduent Incorporated (NASDAQ:CNDT)

    8/11/25 4:06:00 PM ET
    $CNDT
    $FI
    $IART
    Real Estate
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    GeminiBio Appoints Mike Stella to Board

    Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

    2/18/25 9:00:00 AM ET
    $AMGN
    $GSK
    $JNJ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    $MRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Merck & Company Inc. (Amendment)

    SC 13G/A - Merck & Co., Inc. (0000310158) (Subject)

    2/13/24 4:55:49 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Merck & Company Inc. (Amendment)

    SC 13G/A - Merck & Co., Inc. (0000310158) (Subject)

    2/9/23 10:54:48 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Merck & Company Inc. (Amendment)

    SC 13G/A - Merck & Co., Inc. (0000310158) (Subject)

    2/9/22 3:15:54 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care